Comparative Pharmacology
Head-to-head clinical analysis: DURAGESIC 50 versus ZIPAN 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAGESIC 50 versus ZIPAN 25.
DURAGESIC-50 vs ZIPAN-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a potent synthetic opioid agonist primarily at μ-opioid receptors, with additional weak affinity for κ- and δ-opioid receptors. It increases potassium conductance and decreases calcium influx, leading to hyperpolarization and reduced neurotransmitter release, resulting in analgesia and sedation.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity by blocking serotonin reuptake into presynaptic neurons.
Apply one 50 mcg/h transdermal system every 72 hours; initiate at 25 mcg/h in opioid-naive patients; titrate based on response and tolerability.
25 mg orally twice daily
None Documented
None Documented
Mean terminal elimination half-life 20–27 h (range 13–40 h). Prolonged with hepatic impairment, elderly, or obesity. Clinical context: Requires ~5 days to reach steady state; accumulation risk with continuous use.
Terminal elimination half-life: 6-8 hours in adults; may be prolonged (up to 12 hours) in elderly or patients with renal impairment (CrCl <30 mL/min).
Primarily renal: ~75% as metabolites (mostly norfentanyl, <10% unchanged fentanyl); ~9% biliary/fecal; <10% excreted in urine as unchanged drug.
Primarily renal excretion of unchanged drug (70-80%); fecal elimination accounts for 15-20% via biliary excretion; less than 5% as metabolites.
Category C
Category C
Opioid Analgesic
Opioid Analgesic